EUCTR2009-015386-30-FR进行中（未招募）1 期
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus
SmithKline Beecham Corporation (doing business as GlaxoSmithKline)0 个研究点目标入组 0 人开始时间: 2009年10月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female, 18 to 75 years of age, inclusive, with a historical diagnosis of type 2 diabetes mellitus who is currently treated with insulin glargine, or other
- •intermediate- or long-acting insulin, with or without oral antidiabetic medications but
- •who is experiencing inadequate glycemic control and who is willing and capable of
- •participating in a regimen of intensive insulin administration. A subject who has been on an intermediate- or long-acting insulin for =6 months but <5 years, and, in spite of dosage adjustments based on home blood glucose monitoring, is unable to achieve a HbA1c of <7%. These subjects must be capable and willing to transition
- •from a simple basal insulin regimen to an intensified regimen
- •2. BMI =20kg/m2 and =45 kg/m2
- •3. Fasting C-peptide =0.8 ng/mL (=0.26 nmol/L)
- •4. HbA1c between 7.0% and 10.5%, inclusive, at Visit 5 (Week –1). The HbA1c value
- •may be checked up to 4 times, and if the average of these determinations meets the
- •criterion, the subject may be randomly assigned to treatment
- •5. For the regular use of other medications (does not include medications excluded by the protocol [see Section 5.6.2, for example, weight loss medications are excluded]), it is preferred that the subjects are receiving a stable dose for at least 4 weeks before Screening; however, as necessary during the Run-in/Stabilization Period and the Treatment Period, prescription or over-the-counter medications are allowed and may be adjusted by the investigator to optimize treatment (e.g., increase or decrease of medication to treat blood pressure or hyperlipidemia in accordance with accepted local medical practice and relevant guidance documents)
- •6. Use of oral or systemically injected glucocorticoids is generally not allowed within
- •3 months before randomization; however, short courses of oral steroids (single dose
- •or multiple doses for up to 2 days) may be permitted provided these cases are discussed with the medical monitor. Inhaled, intra-articular, and topical
- •corticosteroids are allowed
- •7. Hemoglobin =11 g/dL (=110 g/L) for male subjects and =10 g/dL (=100 g/L) for
- •female subjects
- •8. Creatinine clearance >60 mL/min (calculated using the Cockcroft-Gault formula)
- •9. Thyroid-stimulating hormone level is normal or clinically euthyroid as demonstrated
- •by further thyroid tests (e.g., T4, T3, thyroid-binding globulin)
- •10. Female subjects of childbearing potential (i.e., not surgically sterile and/or not
- •postmenopausal) must be practicing adequate contraception. Methods of adequate
- •contraception include the following: abstinence, injectable progestogen, implants of
- •levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device or intrauterine system, male partner sterilization (vasectomy with
- •documentation of azoospermia) before the female subject’s entry into the study and
- •this male partner is the sole partner for that subject, double-barrier method (condom
- •and occlusive cap plus nonoxynol-9), or oral contraceptives in combination with a second method of contraception (e.g., cond
排除标准
- •1. History of cancer, other than squamous cell or basal cell carcinoma of the skin, that
- •has not been in full remission for at least 3 years before Screening. (A history of
- •treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is
- •2. History of treated diabetic gastroparesis
- •3. Current ongoing symptomatic biliary disease or history of pancreatitis
- •4. History of significant gastrointestinal surgery, including gastric bypass and banding, antrectomy, Roux-en-Y bypass, gastric vagotomy, small bowel resection, or
- •surgeries thought to significantly affect upper gastrointestinal function
- •5. Recent (as defined below) clinically significant cardiovascular and/or cerebrovascular disease including but not limited to the following:
- •Previous history of stroke or transient ischemic attack within 1 month before
- •Screening. However, subjects who are deemed clinically stable by the investigator may be enrolled 3 months after the cerebrovascular event
- •Acute coronary syndrome, which includes the following:
- •Documented MI within the 2 months before Screening and during the period up until receiving the first dose of study medication
- •Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within the 2 months before Screening and during the period up until receiving the first dose of study medication
- •Unstable angina not responsive to nitroglycerin within the 2 months before Screening and during the period up until receiving the first dose of study medication
- •Unstable cardiac rhythm, however, as an example, controlled atrial fibrillation is
- •Current or history of heart failure (New York Heart Association class I to IV).
- •Note: Investigators must consult the approved product labeling for TZD in their country to determine a subjects’ eligibility to participate in this study if they are
- •currently taking a TZD
- •Resting systolic pressure is >160 mm Hg and/or diastolic pressure >100 mm Hg.
- •If the subject’s systolic blood pressure is >160 mm Hg or the subject’s diastolic
- •blood pressure is >100 mm Hg at Screening, the blood pressure readings may be
- •repeated at 5-minute intervals for a total of 3 determinations. If the averages of
- •the systolic or diastolic pressure readings still do not meet the criteria, the subject can be treated and rescreened. It is preferred that subjects be on a stable dose of medication for at least 4 weeks before being rescreened; however, when stable, they may be rescreened at the discretion of the investigator.
- •Should a subject not meet this criterion on Visit 6 (first dose of study medication
- •following the randomization visit), the subject may continue in the study at the
- •discretion of the investigator with the understanding that the subject’s hypertension will be monitored and treated in accordance with accepted local medical practice and relevant guidance documents
- •QTc interval (Fridericia) >470 ms confirmed by a central reader at Scree
研究者
相似试验
已完成
3 期
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine.CTRI/2010/091/000071GlaxoSmithKline500
进行中（未招募）
1 期
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes MellitusMedDRA version: 12.0 Level: LLT Classification code 10045242 Term: Type II diabetes mellitusType 2 Diabetes MellitusEUCTR2009-015386-30-GBSmithKline Beecham Corporation (doing business as GlaxoSmithKline)
进行中（未招募）
不适用
A research study comparing the long term safety (48 weeks) of the investigational drug SUN101 (glycopyrrolate) given by a nebulizer, with tiotropium bromide inhalation powder (Spiriva®) in patients with Chronic Obstructive Pulmonary Disease (COPD).MedDRA version: 17.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-002696-18-CZSunovion Respiratory Development Inc.1,050
进行中（未招募）
不适用
A research study comparing the long term safety (48 weeks) of the investigational drug SUN101 (glycopyrrolate) given by a nebulizer, with tiotropium bromide inhalation powder (Spiriva®) in patients with Chronic Obstructive Pulmonary Disease (COPD).EUCTR2013-002696-18-HUSunovion Respiratory Development Inc.1,050
进行中（未招募）
不适用
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes MellitusMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2009-015386-30-DEGlaxoSmithKline LLC565